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Aminoglycosides for Intra-Abdominal Infection: 
Equal to the Challenge?
JEFFREY A. BAILEY,1 KATHERINE S. VIRGO,1 JOSEPH T. DIPIRO,2 AVERY B. NATHENS,3
ROBERT G. SAWYER,4 and JOHN E. MAZUSKI1
ABSTRACT
Background: Aminoglycosides, combined with antianaerobic agents, have been used widely
for the treatment of intra-abdominal infection. However, some prospective randomized con-
trolled trials and other data suggested that aminoglycosides were less efficacious than newer
comparators for the treatment of these infections. We therefore performed a meta-analysis of
all prospective randomized controlled trials utilizing aminoglycosides to reevaluate the effi-
cacy of these agents for the treatment of intra-abdominal infection.
Methods: Published English-language prospective randomized controlled trials comparing
aminoglycosides with other agents for treatment of intra-abdominal infection were identified
by MEDLINE search. For each study, data were collected regarding the number of patients
enrolled and evaluated, their basic demographic characteristics, the sources of the intra-ab-
dominal infections, the number of failures as determined by the study investigators, quality
score, and the use of serum drug concentrations to monitor aminoglycoside therapy. These
data were combined to calculate odds ratios for risk of therapeutic failure, which were as-
sessed for significance using Chi-square analysis.
Results: Forty-seven prospective randomized controlled trials comparing aminoglycosides
to other agents were identified. These were published between 1981 and 2000, and included
a total of 5,182 evaluable patients. Analysis of all studies combined revealed an odds ratio
that slightly, but significantly, favored the comparators. After excluding six trials using com-
parators that lacked accepted antianaerobic efficacy, the odds ratio more strongly favored com-
parators. Trials published since 1990 also notably favored comparators. Analyzing results by
quality score or the use of aminoglycoside monitoring did not alter these findings.
Conclusions: In this meta-analysis, aminoglycosides were less efficacious than newer com-
parators for the treatment of intra-abdominal infection. Given the well-known toxicities of
these agents, we conclude that they should not be used as first-line therapy for these infec-
tions.
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2University of Georgia College of Pharmacy and Department of Surgery, Medical College of Georgia, Augusta,
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AMINOGLYCOSIDES IN COMBINATION with anti-anaerobic agents were the first antimicro-
bial regimens recognized as efficacious for the
treatment of patients with intra-abdominal in-
fection. Some still consider this regimen to be
the gold standard of antimicrobial therapy for
these infections. However, aminoglycosides
have substantial nephrotoxicity and ototoxic-
ity. In addition, they require monitoring of
serum concentrations for optimal utilization.
Thus, other agents with equal efficacy that do
not exhibit such toxicity or need intensive mon-
itoring might be more desirable for the treat-
ment of patients with intra-abdominal infec-
tions.
A large number of prospective randomized
controlled trials have compared the efficacy of
aminoglycosides against newer antimicrobials
to identify such alternative regimens. A few of
these trials actually demonstrated greater effi-
cacy of the comparator agents, calling into
question the continued use of aminoglycosides
as first-line agents for the treatment of intra-ab-
dominal infections [1]. However, nearly all tri-
als were designed only to detect therapeutic
equivalence, which allows for differences in ef-
ficacy as high as 15–20% between regimens;
very few, if any, of the trials were actually pow-
ered to detect therapeutic superiority. Thus, the
appropriate role of aminoglycosides in the
treatment of intra-abdominal infection is diffi-
cult to ascertain on the basis of the individual
study data.
Meta-analysis provides a tool with which to
aggregate the results of smaller, individual tri-
als, such that statistical analysis may be applied
to answer questions that these individual stud-
ies cannot address [2–5]. In order to re-evalu-
ate the role of aminoglycosides in the treatment
of intra-abdominal infections, we performed a
meta-analysis of all prospective randomized
controlled trials that compared aminoglyco-
side-based regimens against agents from other
antibiotic classes for the treatment of these in-
fections. We hypothesized that these combined
data might make it possible to more defini-
tively answer the question as to whether or not
aminoglycoside-based regimens should still be
considered first-line agents for the treatment of
patients with intra-abdominal infections.
MATERIALS AND METHODS
Study identification and selection
All published English-language prospective
randomized controlled trials that compared an
aminoglycoside in combination with an an-
tianaerobic agent against antimicrobials from
other classes for the treatment of patients with
established intra-abdominal infections were se-
lected for potential inclusion in the meta-analy-
sis. Results available only in abstract form were
not included in this analysis, because most
studies on aminoglycoside use were performed
more than five years ago, and it was not likely
that such trials could be identified and evalu-
ated systematically. Published trials were iden-
tified from a search of the MEDLINE database
using the names of specific aminoglycosides
paired with words and phrases suggesting an
intra-abdominal infection (such as peritonitis,
intra-abdominal abscess, appendicitis). This
search strategy was supplemented by exami-
nation of the references found in various arti-
cles discussing treatment of intra-abdominal
infections, and also by a search of the Cochrane
database.
Published studies identified by this initial
search strategy were then excluded for a vari-
ety of reasons. Studies were not considered
further if the data had not been acquired
prospectively, or if the subjects had not been
randomized. Studies designed to evaluate pro-
phylactic use of antimicrobials for surgical
procedures not involving intra-abdominal in-
fections were also excluded, including those
involving patients undergoing elective ab-
dominal procedures as well as those having
acute intraperitoneal contamination. Trials
that included subjects with infections outside
the abdominal cavity were excluded unless the
results were reported separately for patients
with intra-abdominal infections. Finally, trials
in which patients received an antimicrobial in
addition to an aminoglycoside that was effec-
tive against gram-negative aerobic/facultative
anaerobic bacteria were eliminated, unless that
additional antibiotic was ampicillin or peni-
cillin being provided for enterococcal cover-
age.
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Data abstraction and assessment
The resultant trials were reviewed, and data
were abstracted with regard to year of publica-
tion, total number of patients enrolled, number
of evaluable patients, demographics of evalu-
able patients, patient diagnoses or anatomic
sources of intra-abdominal infection, the spe-
cific aminoglycoside and comparator regimens
used, number of treatment failures as identi-
fied by the individual study investigators, the
use of serum drug levels to monitor aminogly-
coside therapy, and toxicity due to antimicro-
bials. Quality scores were determined using the
method of Jadad et al. [6]. Scores ranged from
zero to five, with five representing the highest
quality score that could be achieved (Table 1).
All quality scores were determined indepen-
dently by at least two investigators.
Statistical analysis
Risks of therapeutic failure with aminogly-
coside-based therapies relative to risks of ther-
apeutic failure with comparator therapies were
expressed as odds ratios. An odds ratio less
than one favored the aminoglycoside-based
regimens, whereas an odds ratio greater than
one favored the comparator agents. Confidence
intervals were derived for these ratios, with
Chi-square analysis being used to establish sta-
tistical significance. Odds ratios, P values, and
95% confidence intervals were determined for
each individual trial, for all trials combined,
and for trials grouped by year of publication,
comparator class, quality score, percentage of
subjects with appendiceal disease, use of
aminoglycoside monitoring, and enrollment of
pediatric patients [7,8].
To assess trial heterogeneity, the procedure
outlined by L’Abbe et al. was utilized [4]. Pre-
dicted failure rates for aminoglycosides and
comparators were determined by linear re-
gression analysis of all trials, and 95% confi-
dence limits about this derived relationship
were determined. Individual trial results were
then plotted to determine the number of trials
with results outside of those confidence inter-
vals.
RESULTS
Trial and patient characteristics
The initial search strategy identified 112 tri-
als, of which 65 [9–73] were excluded from fur-
ther analysis for the reasons given in Table 2.
Data from 47 publications were included in the
meta-analysis [74–120]. Two studies included
three treatment arms, one of which involved an
aminoglycoside-based regimen [74,76], and
one other study had four separate treatment
arms, two of which involved an aminoglyco-
side-based regimen [84]. These trials were pub-
lished between 1981 and 2000. A total of 7,772
patients were enrolled in the trials, with the
number of patients enrolled in individual tri-
als ranging from 41 to 993. Of these 7,772 pa-
tients, 5,182 (66%) were clinically evaluable by
individual study criteria. The number of clini-
cally evaluable patients in these trials ranged
from 28 to 341.
Study enrollment criteria included known or
suspected intra-abdominal infection based on
physical, laboratory, and radiographic exami-
nations, and findings at the time of operative
or other interventional procedures. Enrollment
criteria usually required the patient to have un-
dergone a source control procedure by the op-
erative or percutaneous route. In fact, only nine
clinically evaluable patients were specifically
identified as having undergone medical ther-
apy only. These patients would not have been
considered to have had “complicated” intra-ab-
dominal infection as defined by the criteria of
Solomkin et al. [121].
Exclusion criteria varied from study to study.
TABLE 1. QUALITY SCORING SYSTEM
Give one point if the study was randomized, and:
Give one additional point if the method of random-
ization was appropriate
Deduct one point if the method of randomization
was inappropriate
Give one point if the study was double blinded, and:
Give one additional point if the method of blinding
was appropriate
Deduct one point if the method of blinding was
inappropriate
Give one point if there was a description of 
withdrawals and dropouts
From Jadad et al. [6].
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Most trials excluded patients outside of specific
age ranges, in order to prevent enrollment of
children in adult studies and vice versa. How-
ever, two trials specifically excluded patients of
advanced adult age [78,102]. The most common
exclusion criteria were pregnancy or lactation,
previous hypersensitivity to trial antimicrobial
agents, recent or concurrent treatment with an-
timicrobials, infection with organisms known
to be resistant to study agents, and concurrent
participation in other clinical trials. Many
studies excluded moribund patients, those not
expected to survive 48 hours, and those with
terminal illnesses. Patients with high-acuity ill-
ness, immunosuppression HIV disease, granu-
locytopenia, and renal or hepatic dysfunction
or failure were variably excluded.
Definitions of success and failure varied
from study to study. Cure was generally de-
fined as resolution of all clinical signs of infec-
tion without the need for additional antimi-
crobial therapy or operative intervention.
Several studies also included a final outcome
defined as improved, in which there was con-
trol of the primary infective process, but with
some form of ongoing clinical disability. For
this meta-analysis, patients classified as im-
proved were considered to be treated success-
fully. Definitions of treatment failure varied
somewhat more widely between studies. Pa-
tients who died as a result of their infections or
who required additional antimicrobials or pro-
cedures, including drainage of wound infec-
tions, to control their infectious process were
generally considered to have failed treatment.
However, patients who developed adverse re-
actions to study medications, who developed
infectious complications outside of the abdom-
inal cavity, or who died as a result of other dis-
ease processes were variously reported as treat-
ment failures, unevaluable, or occasionally as
treated successfully.
Thirty-three of the 47 studies, including 78%
of the evaluable patient population, provided
demographic information. Sixty-seven percent
of these patients were male. The reported age
range was from 6 months to 91 years. In trials
enrolling only adult patients, the mean age was
40 years. Six trials enrolled pediatric patients
only [84,91,96,101,105,106], and one additional
trial included a subset of pediatric patients [86].
In all, 688 of the characterized patients were in
the pediatric age range. Thus, pediatric patients
represented at least 13% of the total population
of clinically evaluable patients.
Among the studies providing adequate in-
formation, the most prevalent source of intra-
abdominal infection was the appendix. A to-
tal of 2,621 patients were described as having
appendiceal disease, representing at least 51%
of all clinically evaluable patients. Of these
2,621 patients, 2,126 (81%) were identified as
having complicated appendicitis (gangrenous,
perforated, or abscessed) and 495 were listed
as having appendicitis, but not otherwise de-
scribed. In all six of the studies enrolling pe-
diatric patients exclusively, the appendix was
the anatomic source of the infection. Other
commonly reported diagnoses or sources of in-
tra-abdominal infection are listed in Table 3.
Randomization of patients resulted in 2,451
being assigned to aminoglycoside-based ther-
apy and 2,731 to comparator therapy. Amino-
glycosides tested were primarily gentamicin or
tobramycin, with netilmicin and amikacin be-
ing used in a few trials (Table 4). The an-
tianaerobic agent used most commonly with
the aminoglycoside was clindamycin, although
metronidazole was used in several trials. In
seven treatment groups, concomitant treatment
with penicillin or ampicillin was required or
permitted.
A variety of comparator regimens were em-
ployed (Table 5). Twenty-two treatment
TABLE 2. REASONS FOR TRIAL EXCLUSION
Design did not test an aminoglycoside plus an
antianaerobic agent against another comparator
regimen [9–26]
Included patients with infections outside the
abdominal cavity, and did not separately tabulate
results for patients with intra-abdominal infection
[27–40]
Primarily evaluated the use of prophylactic, not
therapeutic antimicrobial therapy [41–54]
Not a prospective, randomized controlled trial on
detailed review [55–67]
Data available only in abstract form [68, 69]
Clinical outcomes not documented [70]
Limited number of patients with intra-abdominal
infection [71]
Intraperitoneal antimicrobial therapy [72]
German language publication [73]
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groups received cephalosporins, with or with-
out additional antianaerobic agents, nine re-
ceived carbapenems as monotherapy, and nine
received penicillins with or without beta-lac-
tamase inhibitors. Other regimens tested in-
cluded aztreonam in combination with clin-
damycin, the oxa-beta-lactam agent moxalactam,
and the fluoroquinolone pefloxacin in combi-
nation with metronidazole.
Study quality varied widely, but tended to
be low. Quality scores ranged from 0 to 5, with
the mean score being two. The distribution of
quality scores is indicated in Figure 1.
Outcome analysis
Efficacy. Odds ratios (OR) with 95% confi-
dence intervals (CI) were recalculated for
each trial individually. The results of this
analysis are presented in Figure 2, with trials
organized by date of publication. An odds ra-
tio of less than one indicated that the trial fa-
vored the aminoglycoside-based regimen,
whereas an odds ratio of greater than one fa-
vored the comparator regimen. Differences
between the treatment arms were statistically
significant only in those studies in which the
confidence interval did not include the value
one. Odds ratios could not be established in
four studies in which a 100% success rate was
reported for either the aminoglycoside or
comparator arm [74,92,110,120]. Five studies
demonstrated statistically significant differ-
ences in outcome [76,95,96,99,120], with two
favoring the aminoglycoside-based regimen
[76,120], and three favoring the comparator
regimen [95,96,99]. One study [114] reported
statistical significance in favor of the com-
parator regimen using logistic regression
analysis, but this was not evident using sim-
ple Chi-square analysis.
Initial meta-analysis of data from all 5,182
patients revealed an OR of 1.194 (CI 1.014–
1.407, P 5 0.04), which slightly, but signifi-
cantly, favored the comparator regimens. In re-
viewing the individual odds ratios, however, it
appeared that trials published prior to 1990
were more likely to show therapeutic equiva-
lence, whereas subsequent trials more consis-
tently favored comparator regimens. Pooled
data were therefore analyzed separately for tri-
als published prior to 1990 and for those pub-
lished in 1990 and later. Although no statisti-
cal difference was observed in the aggregate
data published prior to 1990, the results of tri-
TABLE 3. DIAGNOSIS OR SOURCE OF INTRA-ABDOMINAL INFECTION
Source or diagnosis Number of patients
Appendix (total) 2,621
Complicated appendicitis (perforated, gangrenous, abscessed) 2,126
Appendicitis (not otherwise specified) 495
Intra-abdominal abscess 369
Hepatobiliary 354
Peritonitis (not otherwise specified) 302
Gastroduodenal perforation 290
Perforated viscus (not otherwise specified) 184
Large bowel perforation 243
Diverticular disease 100
Small bowel perforation 97
Miscellaneous (not otherwise specified) 173
Other diagnoses 208
TABLE 4. AMINOGLYCOSIDE-BASED REGIMENS
Number of
Agents treatment arms
Aminoglycosides
Gentamicin 26
Tobramycin 15
Gentamicin or tobramycin 1
Netilmicin 4
Amikacin 2
Antianaerobic and other agents
Clindamycin 35
Clindamycin or metronidazole 1
Metronidazole 4
Clindamycin plus ampicillin 3
Clindamycin plus penicillin 1
Metronidazole plus ampicillin 2
Metronidazole plus penicillin 1
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als published from 1990 on more strongly fa-
vored the comparator regimens (OR 1.438, n 5
3,169, CI 1.165–1.775, P 5 0.001; Fig. 3).
Six early trials [74,76,83,91,109,115] em-
ployed comparator regimens that lacked ad-
equate anaerobic coverage according to con-
temporary standards [122]. These trials uti-
lized cephalothin, cefamandole, cefotaxime,
cefoperazone, or ceftriaxone as monotherapy.
The data were therefore reanalyzed after ex-
cluding these six trials. A much greater risk
of therapeutic failure for the aminoglycoside-
based regimens was observed in this re-
analysis (OR 1.296, n 5 4,446, CI 1.085–1.547,
P 5 0.004; Fig. 4).
Data were also analyzed according to the
class of comparator utilized (Fig. 5). Fluro-
quinolones were not analyzed because only
one trial employed these agents. Subset analy-
sis indicated that cephalosporins (OR 1.94, n 5
1,426, CI 1.689–2.230, P 5 0.005), carbapenems
(OR 1.49, n 5 994, CI 1.296–1.712, P 5 0.03),
and moxalactam (OR 2.24, n 5 313, CI
1.944–2.578, P 5 0.002) were favored over the
aminoglycoside-based regimens. Azetreonam
was also favored over aminoglycosides (OR
1.036, n 5 511, CI 0.901–1.190), but this differ-
ence did not reach statistical significance. The
odds ratio favored aminoglycoside-based reg-
imens compared to regimens utilizing any type
of penicillin (OR 0.91, n 5 1,060, CI 0.792–
1.046), but this difference was also not statisti-
cally significant. The trend in favor of amino-
glycosides appeared to be due to studies uti-
lizing ampicillin/sulbactam or amoxicillin/
clavulanate; when studies using these latter
agents were excluded, the odds ratio signifi-
TABLE 5. COMPARATOR REGIMENS
Number of
Agents treatment arms
Cephalosporins 22
Cephalothin (monotherapy) 1
Cefamandole (monotherapy) 2
Cefoxitin (monotherapy) 4
Cefotetan (monotherapy) 2
Cefminox (monotherapy) 1
Cefotaxime (monotherapy) 1
Cefotaxime plus metronidazole 1
Cefoperazone (monotherapy) 1
Cefoperazone plus sulbactam 2
Cefoxatime plus clindamycin 1
Ceftriaxone (monotherapy) 1
Ceftriaxone plus metronidazole 1
Ceftazidime plus clindamycin 1
Cefipime plus metronidazole 1
Carbapenems: 9
Imipenem/cilastatin 6
Meropenem 3
Penicillins 9
Ampicillin/sulbactam 2
Amoxicillin/clavulanate 1
Ticarcillin/clavulanate 3
Piperacillin/tazobactam 2
Piperacillin 1
Aztreonam plus clindamycin 4
Moxalactam 3
Pefloxacin plus metronidazole 1
FIG. 1. Distribution of quality scores.
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cantly favored the remaining extended spec-
trum penicillins (OR 1.18, n 5 808, CI 1.027–
1.357, P 5 0.002).
Study quality did not appear to have a ma-
jor influence on the finding that comparator
regimens were generally favored over amino-
glycoside-based regimens. Trials were sepa-
rated into two aggregates based on a quality
score of less than or equal to two versus three
or greater. In both subsets, the odds ratios fa-
vored the comparator agents, although this was
statistically significant only for the subset with
lower quality scores (quality score # 2, OR
1.26, n 5 2,776, CI 1.007–1.576, P 5 0.05; qual-
ity score $ 3, OR 1.116, n 5 2,406, CI 0.877–
1.420, P 5 ns; Fig. 6).
Since the appendix was the source of the in-
fection in greater than 50% of patients for
whom information was provided, a subset
analysis was performed to determine if this in-
fluenced the results of this meta-analysis (Fig.
7). Forty trials provided sufficient information
to allow separation into subsets based on the
number of clinically evaluable patients who
had appendiceal-related infections. Fifteen tri-
als [76–79,84,91,93,96,97,101,105–107,110,120]
FIG. 3. Odds ratio for all studies and for studies stratified according to year of publication. For all studies P 5 0.04;
for those published prior to 1990 P 5 ns; and for those published from since 1990 on P 5 0.001.
FIG. 2. Odds ratios for individual trials. Odds ratios could not be calculated for four trials [74,92,110,120] because
the failure rate was zero in the aminoglycoside or comparator arm. Of these studies, that by Yellin et al. [120] demon-
strated statistical significance in favor of the aminoglycoside-based regimen. *P , 0.05 by two-tailed test; **P , 0.05
by logistic regression analysis carried out in original trial, but not when recalculated by Chi square analysis.
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enrolled patients with appendicitis exclusively.
In these trials, the OR favored the aminoglyco-
side-based regimens, although this did not
reach statistical significance (OR 0.83, n 5
1,108, CI 0.582–1.078, P 5 ns). In a second set
of seven trials [75,89,103,108,116–118], greater
than 50% of the patients had the appendix as
the source of their infection, although the trials
were not limited to patients with appendicitis.
In this subset, only a very slight advantage was
observed for the comparator-based regimens
(odds ratio 1.060, n 5 888, CI 0.844–1.303, P 5
ns). However, in the remaining studies in
which fewer than 50% of the enrolled patients
had the appendix as the source of their infec-
tions [81,85,87,88,90,92,94,98–100,104,109,110,
112,114,115,119], the comparator agents were
significantly favored over aminoglycosides
FIG. 4. Odds ratio for all studies and for studies remaining after elimination of those judged to have inadequate
anaerobic coverage in the comparator arms. For all studies P 5 0.04; for studies remaining after elimination of com-
parators with inadequate anaerobic efficacy P 5 0.001.
FIG. 5. Odds ratios for studies grouped according to class of comparator. For carbapenems P 5 0.03; for
cephalosporins P 5 0.005; for any penicillins with or without beta-lactamase inhibitors (PCN/B) P 5 ns; for peni-
cillin/beta lactamase inhibitor combinations remaining after eliminating regimens utilizing ampicillin/sulbactam or
amoxicillin/clavulanate (extended spectrum PCN/B) P 5 0.002; for the monobactam P 5 ns; and for the oxa-beta-
lactam P 5 0.002.
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FIG. 6. Odds ratios for studies stratified by quality scores. For studies with quality scores of three or greater P 5
ns; for studies with quality scores of two or less P 5 0.05.
FIG. 7. Odds ratios for studies stratified according to the source of infection. For studies including only patients
with appendicitis and those in which greater than 50% of the patients had appendicitis P 5 ns; for studies in which
less than 50% of the patients had appendicitis P 5 0.002.
(OR 1.399, n 5 2,704, CI 1.133–1.728, P 5 0.002).
Thus, the source of the infection did appear to
influence the results, with comparators being
more strongly favored in trials involving larger
numbers of patients with diagnoses other than
appendicitis.
In 33 of the 47 studies, some monitoring of
serum aminoglycoside concentrations was un-
dertaken, although the manner in which this
was used to adjust aminoglycoside dosing was
not described in many articles. Trials were
stratified according to whether or not serum
drug monitoring was performed. Odds ratios
favored comparators in both subsets, although
these ratios did not reach statistical significance
in either subset (group in which serum concen-
trations were monitored: OR 1.197, n5 3,670,
CI 0.990–1.448, P 5 ns; group not monitored:
OR 1.190, n5 1,512, CI 0.864–1.641, P 5 ns.).
A separate analysis was also carried out on
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the six trials that enrolled pediatric patients ex-
clusively [84,91,96,101,105,106]. In this analysis,
comparators were very slightly favored, but
this difference was not significant.
Heterogeneity. Study heterogeneity was as-
sessed by comparing actual and predicted rates
of therapeutic failure for aminoglycoside-based
and comparator regimens. As shown in Fig. 8,
nearly two-thirds of the actual results reside
outside of the predicted confidence interval, in-
dicating significant heterogeneity of treatment
effects among the various trials.
Aminoglycoside toxicity. Forty-two trials ex-
plicitly reported on nephrotoxicity, although
definitions varied widely and occasionally
were not described at all. Among these 42 tri-
als, nephrotoxicity occurred in 98 patients, an
incidence of 2.3%. Seventy of these patients
were from trials that utilized some form of
aminoglycoside monitoring, and 28 of these pa-
tients were from trials that did not report such
monitoring. The incidences of nephrotoxicity in
these two subsets were not statistically differ-
ent by Chi square analysis.
There were only five trials involving 490
aminoglycoside-treated patients that reported
explicitly on ototoxicity. Among these trials, six
patients were found to have ototoxicity, an in-
cidence of 1.2%. Five of these patients devel-
oped auditory toxicity, and one developed
vestibular toxicity. Only two trials specifically
described the use of some form of auditory
monitoring or assessment by audiometry to de-
tect ototoxicity. Two patients (0.9%) developed
ototoxicity as a result of aminoglycoside expo-
sure in those trials.
DISCUSSION
Effective treatment of intra-abdominal in-
fection requires adequate drainage of peri-
toneal suppuration and optimally, definitive
surgical control of infective foci. As adjuncts
FIG. 8. Test of heterogeneity. The linear regression line for predicted rates of therapeutic failures with aminogly-
coside-based regimens and comparator regimens, and the 95% confidence interval about this regression line are in-
dicated. Data points indicate all individual studies.
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to operative or percutaneous drainage, the
role of antimicrobials is to limit the persistence
of remaining infectious microorganisms. An-
timicrobial therapy is given empirically, and
culture results, even when obtained, rarely 
influence therapeutic choices or results. To 
be effective, antimicrobials must have activity
against both the aerobic/facultative anaerobic
bacteria and strictly anaerobic organisms
found with intra-abdominal infections. An-
timicrobial regimens that do not target both Es-
cherichia coli and Bacteroides fragilis increase the
risk of clinical treatment failure [122].
An aminoglycoside in combination with an
antianaerobic agent was the first regimen gen-
erally recognized as efficacious in the treatment
of intra-abdominal infection [122]. This combi-
nation is also relatively inexpensive. However,
the ototoxicity and nephrotoxicity of amino-
glycosides raise concerns. Routinely, serum
drug concentrations are monitored to avoid
toxicity and improve efficacy of these agents.
However, even with careful monitoring of
serum drug concentrations, aminoglycosides
can still have significant toxic effects. The costs
associated with pharmacokinetic surveillance
as well as those associated with adverse effects
may cancel out any cost savings that these
agents appear to offer [123,124].
Since the first use of aminoglycosides for in-
tra-abdominal infection, several newer antimi-
crobials effective against aerobic/facultative
anaerobic gram-negative bacilli have become
available. These agents include carbapenems, a
number of second-, third- and fourth-genera-
tion cephalosporins, newer extended-spectrum
penicillins (many times combined with beta-
lactamase inhibitors) oxa-beta-lactams, mono-
bactams, and fluoroquinolones. These agents
have been compared to aminoglycosides for
the treatment of patients with intra-abdominal
infection in many prospective randomized con-
trolled trials. Virtually all of these trials have
demonstrated therapeutic equivalence of these
newer comparators with aminoglycosides. A
few have identified statistically significant dif-
ferences in endpoints, some in favor of amino-
glycosides and some in favor of comparator
agents [123]. Particularly in the light of these
latter studies, some have questioned the thera-
peutic role of aminoglycoside regimens as first-
line agents for the treatment of patients with
intra-abdominal infections. However, despite
the large number of studies that have been car-
ried out, the data from individual trials are in-
adequate to make this assessment definitively.
Meta-analysis provides a means to perform
a structured and quantitative evaluation of the
published literature and other studies ad-
dressing a specific clinical issue. This tech-
nique of mathematically pooling data from
multiple trials may provide answers to ques-
tions when prior studies have shown conflict-
ing or insignificant results, usually because of
an inadequate sample size. In the present in-
vestigation, meta-analysis revealed a slight,
but significant advantage to comparator agents
compared to aminoglycoside-based regimens
for the therapy of intra-abdominal infections.
Although in theory, the quantitative aspects
of the meta-analytic tool may surpass the lim-
itations of individual trials, in practice the reli-
ability of the final product may be compro-
mised by faulty design of the meta-analytic
study itself as well as by poor quality of the in-
dividual data being pooled [1–5,125–127]. With
regard to the quality of the pooled data, we
sought to use the best evidence available for
this analysis. This should be found in prospec-
tive randomized controlled trials published in
peer-reviewed literature. In order to avoid in-
advertent exclusion of relevant data, we uti-
lized multiple overlapping search strategies to
identify all publications that met our inclusion
criteria, and only eliminated studies after they
were reviewed fully.
For this meta-analysis, the few reports pub-
lished in abstract form and unpublished data
were not included as they tended to be quite
old. We did not believe that this small amount
of additional information was likely to be rep-
resentative and unbiased, and was unlikely to
influence appreciably the overall results. Due
to limited resources it was not possible to re-
view potentially useful prospective random-
ized controlled trials published in languages
other than English, and these were excluded by
our search strategy. This represents a limitation
in the universal applicability of this data, which
could potentially be addressed by future in-
quiry.
In recent years, a number of techniques have
326 BAILEY ET AL.
been developed to assess the quality of
prospective randomized controlled trials. Ex-
ternal validation and evaluation of these tech-
niques continues to evolve [6,125–127]. The 
primary goal of these scoring systems is to de-
termine the likelihood of study bias. For this
meta-analysis, we chose to score the compo-
nent trials using the method described by Jadad
et al. [6], because of its practical simplicity and
familiarity to the authors. Essentially, the qual-
ity scores of the articles included in this analy-
sis were normally distributed, with overall
mean and median scores between two and
three (Fig. 1). The overall low quality scores of
many of the studies in this analysis is some-
what disturbing, however, raising the possibil-
ity of bias if lower quality studies favored one
or the other treatment options. Therefore, we
analyzed subsets that had been stratified ac-
cording to their quality scores. The results in
these subsets did not appear to deviate notably
from the results of all studies combined, sug-
gesting that study quality was not responsible
for the observed advantage of comparators
over aminoglycosides.
Some dismiss the use of meta-analyses en-
tirely, noting that such studies are usually de-
rived from combinations of heterogeneous
data. Optimally, meta-analyses should be
based on a series of homogenous studies, and
the overall study results should mimic the re-
sults of the component studies. Unfortunately,
such an ideal can rarely be realized. We em-
ployed one method of assessing study hetero-
geneity, by evaluating the variability of indi-
vidual study results from the overall outcome
[4]. As applied to our results, this method iden-
tified a significant degree of heterogeneity.
Thus, the results of this meta-analysis need to
be interpreted with some degree of caution.
Nonetheless, some degree of trial heterogene-
ity is virtually inevitable, given the heteroge-
neous character of intra-abdominal infections
in general, which would be further amplified
by the numerous differences observed in over-
all study design and quality. Ultimately, future
large-scale trials of aminoglycosides for the an-
timicrobial therapy of intra-abdominal infec-
tions are unlikely to be performed. Thus, the
heterogeneous data obtained from trials pub-
lished up to now will have to suffice for mak-
ing recommendations with regard to the use of
these agents.
In 1984, Solomkin et al. [128] provided a crit-
ical evaluation and review of study design and
outcome reporting in trials of antimicrobials for
intra-abdominal infection, based on the evalu-
ation of sixteen trials published in the early
1980’s. Some of the problems identified were
inclusion criteria that permitted enrollment of
patients with intra-abdominal contamination
but not intra-abdominal infection; exclusion
criteria that prevented enrollment of seriously
ill patients or patients with postoperative or re-
current infections; nonuniform reporting of in-
fectious diagnoses; and nonuniform reporting
of outcomes, including the basis for designat-
ing patients as treatment failures.
Review of this larger and later collection of
studies unfortunately revalidates these find-
ings of Solomkin et al. Of the 5,182 evaluable
patients, at least 1,100 (20%) had diagnoses po-
tentially indicative of contamination but not
necessarily infection. Many exclusion criteria
that prevented enrollment of seriously ill pa-
tients were also encountered in this analysis.
The mean adult age in this analysis of 40 years
and the large number of patients with the ap-
pendix as the source of their intra-abdominal
infection imply that patients enrolled in these
studies were relatively younger and healthier
than many with intra-abdominal infections.
Thus, the applicability of these studies to an
older and sicker population is problematic.
Similarly, problems with regard to uniform re-
porting of infectious diagnosis and uniform cri-
teria for reporting treatment outcome were ev-
ident in this analysis. With regard to this latter
problem, the available data were generally in-
sufficient to permit any attempt at revising re-
ported success and failure rates. Ultimately, it
was necessary to accept the investigator’s des-
ignated outcomes at face value, although the
differing definitions of success and failure
likely contributed to the observed heterogene-
ity [121].
As indicated, the overall analysis favored the
comparator agents over aminoglycosides. The
difference in OR increased when evaluating
only trials published since 1990. These findings
could indicate that it is newer comparator
agents that are more efficacious than amino-
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glycosides for therapy of intra-abdominal in-
fections. However, there exists the possibility
that publication bias accounts in part for these
observations. Particularly in later years, stud-
ies favoring comparator regimens might have
been more likely to be published than studies
favoring aminoglycosides.
The likelihood of publication bias is difficult
to address without having access to the body
of unpublished data collected over the years.
However, the consistency of the results across
a variety of different subset analyses argues
against the possibility that publication bias was
solely responsible for the observed findings.
Perhaps some of the more interesting data
came from subset analyses of different com-
parator classes, including those utilizing some-
what older agents. With the exception of the
subset involving comparators from the peni-
cillin class, all other regimens (carbapenem,
cephalosporin, monobactam, and oxa-betalac-
tam), were favored over aminoglycoside-based
regimens. With comparators from the penicillin
class, the apparent advantage of aminoglyco-
side-based regimens was entirely due to stud-
ies utilizing ampicillin/sulbactam and amoxi-
cillin/clavulanate, agents that have an inferior
spectrum of gram-negative coverage compared
to aminoglycosides. Elimination of these stud-
ies resulted in the finding that extended-spec-
trum penicillin regimens were significantly
more effective than aminoglycoside-based reg-
imens. Another notable finding was that elim-
inating studies that employed comparator
agents now considered to lack adequate an-
tianaerobic activity also shifted the odds ratio
more strongly in favor of the comparators.
Thus, it appeared that comparator regimens
having broad spectrum coverage of aerobic/
facultative anaerobic gram-negative organisms
and adequate anaerobic coverage consistently
demonstrated equivalence or actual superior-
ity compared to aminoglycoside-based regi-
mens. These observations strengthen the hy-
pothesis that newer comparator regimens are
of potentially greater efficacy than aminogly-
coside-based regimens for the therapy of intra-
abdominal infections.
Failure to achieve adequate serum amino-
glycoside concentrations has been cited as one
possible explanation for study results favoring
comparator regimens [114]. In this analysis,
there was no apparent difference in outcome
between those studies that reported monitor-
ing of aminoglycoside serum concentrations
and those that did not. However, the actual
way in which monitoring was used to alter
aminoglycoside dosing regimens was not out-
lined consistently. Very few studies provided
any indication that prompt attainment of ther-
apeutic aminoglycoside had been achieved,
and none of the studies employed once daily
dosing of aminoglycosides. Thus, the possibil-
ity that prolonged subtherapeutic concentra-
tions of aminoglycosides contributed to in-
creased failure rates remains a possibility.
In over 50% of the patients enrolled in these
trials, the appendix was the source of the intra-
abdominal infection. Although over 80% of
these patients were described as having com-
plicated appendicitis, some of those patients
had gangrenous, but not perforated appendici-
tis. The remaining 20% of patients were only
described as having appendicitis, without any
other information being provided with regard
to the nature of the disease process. Thus many
of these patients with appendicitis may not
have required greater than 24 h of antibiotics
according to the Surgical Infection Society
guidelines of Bohnen et al [1]. Many patients
who had the appendix as their source of infec-
tion were enrolled in pediatric studies, and it
is likely that many adult patients with appen-
dicitis were also relatively young and healthy.
It is notable that aminoglycosides were fa-
vored, although not significantly, in the stud-
ies in which all or a majority of the patients had
the appendix as the source of their infections.
Conversely, in the trials in which the majority
of patients did not have the appendix as the
source of infection, a significantly greater risk
of therapeutic failure was observed in patients
receiving aminoglycosides. Thus, the amino-
glycoside-based regimens may actually have
been less efficacious in patients with more se-
rious infectious processes.
The incidence of nephrotoxicity reported
with aminoglycoside use was two percent in
this study population. Although this seems re-
assuringly low, not all studies consistently re-
ported nephrotoxicity, and little can be said
about the incidence of this complication in
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older, higher-risk patients. Nonetheless, the
costs of monitoring serum aminoglycoside con-
centrations for evidence of nephrotoxicity cer-
tainly add substantially to the burden of pro-
viding aminoglycoside therapy.
With regard to ototoxicity, only a tiny mi-
nority of studies reported any form of routine
monitoring for this complication. Six patients
were reported to have sustained some form of
ototoxic injury associated with aminoglycoside
therapy, although this was likely to have been
underreported. The development of amino-
glycoside-induced ototoxicity, as opposed to
nephrotoxicity, is generally thought to be per-
manent, resulting in life-long disability. Thus,
it is somewhat disturbing that routine moni-
toring was not employed to detect this com-
plication in the vast majority of trials. As part
of the assessment of the utility of these agents,
this type of toxicity needs to be considered.
In conclusion, this meta-analysis indicates
that aminoglycosides are no more efficacious,
and possibly less so than newer comparator
agents for the treatment of patients with intra-
abdominal infections. Thus, these data refute
the notion that aminoglycoside-based regi-
mens should be considered the “gold stan-
dard” for the treatment of these infections. Al-
though the cost of these pharmaceuticals by
themselves may be low, the costs associated
with monitoring add appreciably to the over-
all expense of these regimens, and may negate
any cost advantage. In addition, these agents
have a narrow therapeutic index, with well-
known toxic side effects. Unfortunately,
prospective evaluation of toxicity, particularly
ototoxicity, has been poorly addressed in
many of these clinical trials. For all these rea-
sons, we do not believe that aminoglycosides
should be utilized as first-line therapeutic
agents for the treatment of intra-abdominal in-
fection. Their use should probably be reserved
for patients with severe allergic or anaphylac-
tic reactions to most other classes of antibiotics,
or to those patients who have failed treatment
with other agents.
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Comp 
Author N N ev AG agent AG Combo Agent Comp Agent Comp Class Comb Agent
Gripenberg 047 047 Tobra Clinda Cephalothin Cephalosporin Cephalexin
Stone 1982 249 155 Gent Clinda Cefotaxime Cephalosporin
Berne* 237 130 Gent Clinda Cefamandole or Cephalosporin
Cefperazone
Strom 156 156 Gent Clinda Moxalactam oxa-betalactam
Baird 144 056 Gent Clinda Cefoperazone or Cephalosporin
Cefperazone
Schentag 100 098 Tobra Clinda Moxalactam oxa-betalactam
Biron 042 037 Tobra Clinda Cefotaxime Cephalosporin Metronidazole
Busuttil 065 065 Gent Clinda Cefomandole Cephalosporin
Stone 1984 099 099 Gent Clinda Ceftriaxone Cephalosporin
Malangoni 170 112 Tobra Clinda Cefoxitin Cephalosporin Placebo
Yellin 197 105 Gent Clinda Ampicillin PCN/B Lactam sulbactam
Guerra 041 028 Gent Clinda Imipenem Cilastatin
Lau 122 105 Gent Metronidazole Cefoxitin Cephalosporin
Study Group of IAI 123 083 Gent Clinda Ampicillin PCN/B Lactam sulbactam
Gozenbach 093 093 Netilmicin Clinda Imipem Carbapenem Cilastatin
Leaper 045 043 Gent Amp + Clinda Imipem Carbapenem Cilastatin
Sirinek 1987 124 105 Gent Clinda Cefoxitin Cephalosporin
Berne 1987 162 084 Gent Clinda Azetreonam Monobactam Clinda
Stellato 105 059 Tobra Clinda Moxalactam oxa-betalactam
Huizinga 100 088 Gent Amp + Metronidazole Cefotetan Cephalosporin
Birolini 165 156 Tobra Clinda Azetreonam Monobactam Clinda
Fink 112 045 Gent Clinda Ticarcillin PCN/B Lactam Clavulanate
Schmitt 064 064 Netilmicin Pen G + Metronidazole Amoxicillin PCN/B Lactam Clavulanate
Poenaru 104 104 Tobra Clinda or Metronidazole Imipem Carbapenem Cilastatin
Solomkin** 290 162 Tobra Clinda Imipem Carbapenem Cilastatin
Bubrick 094 068 Tobra Clinda Ceftazidime Cephalosporin Clindamycin
Jauregui* 152 110 Gent Clinda Cefoperazone Cephalosporin sulbactam
Kooi* 100 100 Netilmicin Metronidazole Ceftazidime Cephalosporin Metronidazole
Swedish Study 271 184 Gent Metronidazole Pefloxacin Quinolone Metronidazole
Luke* 201 190 Netilmicin Amp +Metronidazole Ceftriaxone Cephalosporin Metronidazole
Meller 078 056 Gent Clinda Cefoxitin Cephalosporin
Schropp 154 97 Gent Amp + Clinda Cefoxatime Cephalosporin Clinda
Williams 316 209 Tobra Clinda Azetreonam Monobactam Clinda
Sirinek 1991 099 099 Gent Clinda Ticarcillin PCN/B Lactam Clavulanate
Eckhauser 145 117 Gent/Tobra Clinda Imipem Carbapenem Cilastatin
Berne 1993 156 096 Gent Clinda Cefipime Cephalosporin Metronidazole
Polk 331 147 Gent Clinda Piperacillin PCN/B Lactam Tazobactam
Greenberg 076 076 Gent Clinda Cefoperazone Cephalosporin sulbactam
Hopkins 114 076 Amikacin Clinda Cefotetan Cephalosporin
Barboza 067 062 Amikacin Clinda Azetreonam Monobactam Clinda
Condon 177 127 Tobra Clinda Meropenem Carbapenem
Dougherty 993 341 Gent Clinda +/- Amp Ticarcillin PCN/B Lactam Clavulanate
Shyr 077 076 Gent Clinda Piperacillin PCN/B Lactam Tazobactam
Berne 1996 228 129 Tobra Clinda Meropenem Carbapenem
Wilson 427 191 Tobra Clinda Meropenem Carbapenem
Ciftci (Ceftriaxone) 100 100 Tobra PCN + Ornidazole Ceftriaxone Cephalosporin Ornidazole
Ciftci (Piperacillin) 100 100 Tobra PCN + Clinda Piperacillin PCN/B Lactam
Torres 160 152 Gent Metronidazole Cefminox Cephalosporin
APPENDIX: TRIAL DATABASE
N, number of patients enrolled; N ev, number of evaluable patients; AG, aminoglycoside; AG s, number of evaluable
aminoglycoside treatment successes; AG #, total number of evaluable subjects on aminoglycoside arm; C s, number of
evaluable comparator treatment successes; C #, total number of evaluable subjects on comparator arm; Q, quality score; N
Appy, number of evaluable pediatric patients; PK 1 5 y, AG pharmacokinetic monitoring was reported; Year, year of
study publication; 1 C/Ana, comparator regimen with accepted anti-anaerobe efficacy; ORRF, odds ratio; CI, confidence
interval; Clinda, clindamycin; PCN, penicillin; Gent, gentamycin; Tobra, tobramycin; Amp, ampicillin.
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AG S AG # C S C # Q N Appy N Peds PK 15 y Year 1 5 C/Ana ORRF Lower CI Upper CI
022 027 011 020 0 047 047 0 1981 0 0.278 0.075 1.031
065 077 065 078 1 026 000 0 1981 0 0.923 0.392 2.174
039 040 073 090 3 130 000 1 1982 0 0.110 0.014 0.859
045 079 065 077 0 037 000 0 1982
016 016 034 040 3 NR NR 0 1983 0 0 0
037 049 036 049 2 013 000 1 1983 1 00.898 0.362 02.229
014 015 020 022 2 015 NR 0 1984 1 00.714 0.059 08.665
028 034 024 031 1 NR NR 0 1984 0 00.735 0.217 02.486
038 052 039 047 2 20 000 0 1984 0 01.796 0.676 04.77
042 053 049 059 3 22 000 1 1985 1 01.283 0.496 03.32
038 038 059 067 4 105 000 1 1985 1 0 0
014 016 012 012 2 007 000 1 1985
050 052 051 053 3 105 NR 1 1986 1 01.020 0.138 07.525
036 037 040 046 3 NR 000 1 1986 1 00.185 0.021 01.613
043 046 042 047 2 053 000 1 1987 1 00.586 0.132 02.609
022 024 016 019 2 005 000 1 1987 1 00.485 0.072 03.247
049 051 050 054 3 105 NR 1 1987 1 00.510 0.089 02.914
027 028 054 056 2 084 000 1 1987 1 1 0.087 11.525
024 030 026 029 3 015 NR 1 1988 1 02.167 0.487 09.641
028 043 037 045 3 027 000 1 1989 1 02.478 0.922 06.659
069 080 066 076 2 078 NR 0 1989 1 01.052 0.419 02.641
016 025 015 020 3 010 00 1 1989 1 01.688 0.460 06.195
034 035 025 029 1 064 064 0 1989 1 00.184 0.019 01.746
034 052 041 052 1 NR 000 1 1990 1 01.973 0.821 04.744
057 081 067 081 2 039 000 1 1990 1 02.015 0.954 04.256
031 034 031 034 2 NR 000 1 1990 1 1 0.187 05.344
025 034 071 076 3 NR 000 1 1990 1 05.112 1.564 16.710
041 050 049 050 1 100 100 0 1990 1 10.756 1.308 88.473
094 104 064 080 3 115 000 1 1990 1 00.426 0.182 00.997
078 096 088 094 2 076 NR 0 1991 1 03.385 1.279 08.954
026 027 025 029 1 056 056 1 1991 1 00.240 0.025 02.301
042 047 048 050 05 097 097 0 1991 1 02.857 0.527 15.504
089 105 088 104 3 096 000 1 1991 1 00.989 0.466 02.099
036 043 048 056 1 099 NR 1 1991 1 01.167 0.387 03.514
059 064 051 053 2 018 NR 1 1992 1 02.161 0.402 11.619
038 046 047 050 3 096 000 1 1993 1 03.298 0.818 13.296
032 043 090 104 3 079 000 1 1993 1 02.210 0.910 005.364
015 029 033 047 3 024 000 1 1994 1 02.200 0.843 5.745
031 036 036 040 3 076 NR 1 1994 1 01.452 0.358 05.885
027 031 025 031 2 036 000 0 1994 1 00.617 0.156 02.447
056 063 059 064 4 046 000 1 1995 1 01.475 0.442 04.919
115 137 176 204 2 NR 124 1 1995 1 01.202 0.656 02.204
045 046 029 030 3 021 000 1 1995 1 00.644 0.039 10.713
060 066 058 063 5 129 000 1 1996 1 01.160 0.336 04.01
087 094 093 097 5 141 000 1 1997 1 01.871 0.529 06.613
046 050 048 050 2 100 100 0 1997 1 02.087 0.365 11.948
048 050 046 050 2 100 100 0 1997 1 00.479 0.084 02.743
070 076 075 076 2 095 000 1 2000 1 06.429 0.755 54.744
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